News | November 5, 2013
Advanced Cell Diagnostics Announces Genoptix® as their First CLIA Certified RNAscope® Service Provider
Advanced Cell Diagnostic expands RNAscope® technology access through CLIA Service Provider Program
HAYWARD, CA, November 5, 2013—Advanced Cell Diagnostics, Inc. (ACD), a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, today announced that it has introduced a CLIA Certified RNAscope Service Provider program, with Genoptix® BioPharma Services , as the first to be certified. This program is designed to support clinical trials for ACD’s leading pharmaceutical clients to ensure delivery of high quality services performed within a CLIA environment. Each service provider will undergo extensive training on RNAscope technology and is required to pass a rigorous certification procedure. “ACD has established high quality performance standards through RNAscope products and services; this extension of services performed within a CLIA environment further solidifies our commitment. Genoptix is known for quality, service and expertise within the oncology arena. They are an ideal partner to initiate the launch of this program,” said Dr. Yuling Luo, President, CEO and Founder of ACD.
RNAscope is quickly becoming a gold-standard technique to identify and validate RNA biomarkers in tissue for research, molecular diagnostics, and companion diagnostics. ACD’s pharmaceutical clients are rapidly progressing from Phase 1 testing to Phase 2 trials using RNAscope-validated biomarkers. Phase 3 clinical trial testing must be performed within a CLIA environment. “By partnering with highly qualified CLIA Service Providers, our clients can seamlessly transition validated biomarker to Phase 2 or Phase 3 trials. Partners like Genoptix ensure our clients will receive world-class service with the highest data quality necessary for clinical implementation.” said Dr. Luo.
About Advanced Cell Diagnostics, Inc.
Advanced Cell Diagnostics, Inc. is a leader in the emerging field of molecular pathology, developing cell and tissue-based research tools for all areas of biomedical research, and diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the most sensitive method available for RNA in situ hybridization, and the first quantitative and fully automated platform enabling multiplex fluorescent and chromogenic RNA biomarker analysis. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope® technology at www.acdbio.com.
Steve Chen, Ph.D.
Chief Operating Officer